Pancreatic ductal adenocarcinoma

This pilot study tested a wearable device that delivers low-intensity electric fields (TTFields) together with immunotherapy (atezolizumab) and two chemotherapy drugs (gemcitabine and nab-paclitaxel) in 84 people with metastatic pancreatic cancer who had not received prior treatm…

This phase II trial tests whether giving chemotherapy and proton beam radiation before surgery can help people with borderline-resectable pancreatic cancer. The goal is to shrink the tumor enough so that surgeons can remove it completely, with no cancer cells left at the edges. P…

This study tested whether adding a Chinese herbal formula (QingyiHuaji) to standard chemotherapy helps people with stage IV pancreatic cancer live longer. About 305 adults with advanced pancreatic cancer were randomly assigned to receive either the herbal formula plus chemo or a …

This phase II trial tests whether combining niraparib and dostarlimab can control metastatic pancreatic cancer in people who carry BRCA1/2 or PALB2 gene mutations. Niraparib blocks enzymes that cancer cells need to grow, while dostarlimab helps the immune system attack the tumor.…

This study tested two different treatment plans for people with a specific type of pancreatic cancer that is on the edge of being removable by surgery. 130 patients received either chemotherapy alone or chemotherapy plus radiation before surgery. The goal was to see which approac…

This trial is testing whether an experimental drug called JS015, when combined with standard chemotherapy or immunotherapy, is safe and effective for people with advanced solid tumors that have not responded to prior treatment. The study includes patients with certain cancers lik…

This phase 2 trial is testing whether adding hydroxychloroquine to standard radiation and chemotherapy before surgery can better control pancreatic cancer. About 50 people with resectable pancreatic cancer will receive either proton or photon radiation along with capecitabine and…

This trial is testing whether adding high-dose vitamin C (ascorbic acid) to a standard three-drug chemotherapy cocktail can safely and effectively control metastatic pancreatic cancer in people who have not yet received any treatment. The study enrolls adults with stage IV pancre…

This study tested a new drug called brigimadlin (BI 907828) in 99 adults with advanced cancers of the bile duct, pancreas, lung, or bladder that have a specific genetic change (MDM2 amplification). Participants took the drug as a tablet once every 3 weeks. The goal was to see if …

This phase II trial tests whether a combination of four chemotherapy drugs—paclitaxel protein bound, gemcitabine, cisplatin, and hydroxychloroquine—given before surgery can improve outcomes for people with pancreatic cancer that has not spread. The study focuses on patients whose…

This study tests whether endoscopic ultrasound-guided gallbladder drainage can be safely performed using conscious sedation given by the endoscopist, instead of deep sedation or general anesthesia. The trial enrolls elderly, high-risk patients with acute cholecystitis who are not…

This early-phase trial tests a new drug called PEP-010 in people with advanced solid tumors that have spread. The study checks if PEP-010 is safe alone or with chemotherapy (paclitaxel or gemcitabine). About 57 adults with metastatic pancreatic, ovarian, or other solid cancers wi…

This early-phase study tests whether adding losartan (a blood pressure medicine) to a shorter, higher-dose radiation treatment can help people with pancreatic cancer that is hard to remove surgically. The main goal is to check for side effects and find the safest dose. About 22 a…

This trial compares two types of surgery for pancreatic cancer in the body or tail of the pancreas: minimally invasive (laparoscopic or robot-assisted) versus traditional open surgery. The goal is to see if the less invasive approach can remove the tumor just as completely. Adult…

This Phase II trial tested a combination of chemotherapy drugs (FOLFIRINOX) plus the blood pressure drug losartan, followed by proton radiation, in 50 people with locally advanced pancreatic cancer. The goal was to see if this approach could shrink tumors enough to allow complete…

This early-phase trial tested a new drug called RO7496353 combined with an immunotherapy (atezolizumab) and sometimes chemotherapy in 102 people with advanced lung, stomach, or pancreatic cancer. The main goal was to check safety and side effects. Researchers also looked at how t…

This phase 2 trial tested whether adding an immunotherapy drug called botensilimab to standard chemotherapy could help people with metastatic pancreatic cancer who had already progressed on a common chemo regimen (FOLFIRINOX). The study enrolled 81 participants and compared the c…

This study tested a new drug called MK-1200 in 13 people with advanced solid tumors, including stomach, esophageal, bile duct, and pancreatic cancers. The goal was to find safe doses and see if the drug could shrink tumors. The study is complete, but results are not yet available…

This completed phase 1/2 trial tested an experimental drug called Y101D combined with standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for 71 people with advanced pancreatic cancer. The goal was to find a safe dose and see if the combo helps shrink tumo…

This study tested a new drug called NIS793 added to standard chemotherapy for people with metastatic pancreatic cancer that has spread. The goal was to see if the combination could help patients live longer by reducing scar tissue in the tumor. About 511 adults with this advanced…

This early-phase trial tested whether adding a new drug called NP137 to standard chemotherapy (mFOLFIRINOX) is safe and could help shrink tumors in people with locally advanced pancreatic cancer that cannot be removed by surgery. 43 participants received the combination. The main…

This study tested a combination of three drugs (nivolumab, BMS-813160, and GVAX) in 22 people with locally advanced pancreatic cancer who had already received chemotherapy and radiation. The goal was to see if the treatment was safe and could help the immune system better attack …

This study tested a combination of three chemotherapy drugs (paclitaxel protein bound, gemcitabine, and cisplatin) in 34 people with metastatic pancreatic cancer that had not been treated before. If the cancer got worse, a fourth drug (paricalcitol) was added. The goal was to see…

This phase II trial tested a combination of three chemotherapy drugs (nab-paclitaxel, cisplatin, and gemcitabine) in 42 people with metastatic pancreatic cancer that had not been treated before. The main goal was to see how many patients were alive after 12 months. The study also…

This study tested a chemotherapy cocktail called FOLFIRINOX in 72 patients aged 70 or older with metastatic pancreatic cancer. The doses were adjusted based on each person's genetics to reduce side effects while still fighting the tumor. The goal was to see if this approach could…

This study tested a new cancer drug called brigimadlin (BI 907828) in 266 adults with advanced solid tumors that had spread or stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. Brigimadlin is an MDM2 inhibitor tak…

This study looked at 60 people with advanced pancreatic body or tail cancer that couldn't be removed by surgery. It compared a targeted treatment called splenic artery infusion chemotherapy (SAIC), which delivers chemo directly to the tumor's blood supply, with standard chemo giv…

This phase 2 trial tested a combination of chemotherapy drugs given directly into the liver artery for people with pancreatic cancer that had spread only to the liver and stopped responding to standard treatment. The 40 participants received a mix of oxaliplatin, irinotecan lipos…

This study tested a new cancer drug called ERAS-007, given by mouth, together with other targeted therapies in 101 people with advanced colorectal or pancreatic cancers that have certain gene changes. The main goals were to check safety, find the best dose, and see how the drugs …

This study tested a combination of chemotherapy drugs given both before and after surgery for people with early-stage pancreatic cancer. The goal was to shrink the tumor before surgery and kill any remaining cancer cells afterward. 46 participants were enrolled to see if this app…

This study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now lookin…

This large phase III trial tested whether adding the targeted drug erlotinib or chemoradiation to standard chemotherapy after surgery could help people with pancreatic cancer live longer. Over 500 patients who had their tumor removed were randomly assigned to different treatment …

This study tested a modified cold virus called LOAd703 in 51 people with pancreatic cancer. The virus is designed to infect and kill cancer cells while also boosting the immune system. It was given alongside standard chemotherapy, and in some cases an immunotherapy drug, to see i…

This phase 2 trial tested two standard chemotherapy regimens, Folfirinox and Gemcitabine/nab-paclitaxel, in 150 patients with untreated metastatic pancreatic cancer. The goal was to see which works better and to use lab tests to personalize treatment. The study is complete, and r…

This early-phase trial tested whether adding the drug anakinra to standard chemotherapy is safe for people with metastatic pancreatic cancer. Thirteen adults with advanced disease received the combination. The main goal was to check for side effects, not to see if it works.

This completed phase 2 trial tested whether adding an anti-PD-1 immunotherapy drug to standard chemotherapy (modified-FOLFIRINOX) helps patients with locally advanced or borderline resectable pancreatic cancer. The study enrolled 392 participants and compared the combination agai…

This study tested whether giving chemotherapy before surgery (neoadjuvant chemo) helps people with resectable pancreatic cancer live longer. 153 patients were randomly assigned to either standard surgery followed by chemo, or one of two chemo regimens (FOLFOX or FOLFIRINOX) befor…

This study tested whether adding two immunotherapy drugs (pembrolizumab and defactinib) to standard chemotherapy before and after surgery could help the body fight pancreatic cancer better. It involved 28 people with early-stage, removable pancreatic cancer. The goal was to see i…

This study tested a combination of two drugs, pembrolizumab (an immunotherapy) and azacitidine (a drug that affects gene activity), in people with advanced pancreatic cancer that had worsened after initial treatment. The goal was to see if this combination could help control the …

This study looked at 211 people with advanced pancreatic cancer whose first treatment (FOLFIRINOX) stopped working or caused too many side effects. Researchers compared a two-drug combination (gemcitabine and paclitaxel) against gemcitabine alone to see if the combo helped people…

This early-stage trial tested an oral drug called JAB-3312 in 40 adults with advanced solid tumors (like lung, colon, or breast cancer) that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. Researchers also looked …

This phase 2 trial tested a new drug called onvansertib combined with standard chemotherapy for people with metastatic pancreatic cancer that had already been treated once. The study enrolled 41 adults and measured how many patients' tumors shrank. The goal is to find a better se…

This small pilot study tested whether adding a vitamin D-like drug called paricalcitol to standard chemotherapy could help people with advanced pancreatic cancer that had stopped responding. 27 patients received chemotherapy first, then paricalcitol was added if their disease sta…

This study tested several immunotherapy-based drug combinations in 341 people with metastatic pancreatic cancer. Participants were split into two groups: those who had not yet received treatment and those who had already tried one type of chemotherapy. The goal was to see if thes…

This early-phase trial tested different combinations of immunotherapy drugs with standard chemotherapy for people with metastatic pancreatic cancer that had not been treated before. The main goal was to check safety and see if the combinations could shrink tumors or control the d…

This early-phase trial tested a combination of two experimental drugs, vobramitamab duocarmazine and lorigerlimab, in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…

This study tested a new treatment plan for people with advanced pancreatic cancer that has spread. It combined chemotherapy with drugs that change how genes work and boost the immune system. The goal was to see if this approach is safe and can help control the disease. 75 patient…

This early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had signs of remaining disease after standard treatment. The therapy aims to train the immune system to attack…

This study tested a radioactive tracer called [68Ga]FAPI-46, used with a PET scan, to see if it can better detect pancreatic cancer cells. 63 adults with early-stage pancreatic cancer received the tracer before surgery. The goal was to see how well the scan matches the actual can…

This phase 1 trial tested a new radioactive imaging agent called 64Cu-DOTA-ECL1i to see if it can detect a protein called CCR2 in pancreatic tumors using PET scans. The study involved 69 adults with pancreatic ductal adenocarcinoma at various stages. The goal was to see if the sc…

This study tested a new blood test that looks for tiny particles (exosomes) released by cancer cells to find early liver spread in people with pancreatic cancer before they have surgery. The goal is to help doctors decide the best treatment plan by identifying patients at high ri…

This study tested a new radioactive tracer called [18F]FAPI-74 for PET scans in people with gastrointestinal cancers, including liver, bile duct, stomach, pancreatic, and colorectal cancers. The goal was to see if the tracer can accurately detect cancer cells by comparing scan re…

This study tested a drug called telotristat ethyl in 23 people with advanced pancreatic cancer who had lost at least 10% of their body weight. The goal was to see if the drug could help them stabilize or gain weight by reducing bowel movements. Maintaining weight may help patient…

This study tested whether it is safe and possible to collect a blood sample from the portal vein (a major liver blood vessel) during a routine endoscopic ultrasound in 23 people with pancreatic cancer. The goal was to find and count circulating tumor cells (cancer cells in the bl…

This completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…

This study looked at 120 adults with breast, pancreatic, or biliary cancer to see if a new 3D measurement method (TDTP-RECIST) is better than the standard way (RECIST 1.1) for tracking tumor shrinkage before surgery. Researchers compared imaging results with actual tumor tissue r…

This study looked at whether organochlorine pesticides, which build up in body fat over time, are more common in people with pancreatic cancer. Researchers compared fat and urine samples from 56 patients undergoing surgery—some with pancreatic cancer and some without. The goal wa…

This study looked at 300 people with pancreatic cancer to see if changes in a specific type of tumor cell in the blood (called mesenchymal circulating tumor cells) could predict how well they respond to treatment and how long they live. Researchers tracked these cells over time i…

This study looked at the genes in tumors from 332 people with advanced pancreatic cancer. The goal was to see if genetic changes could help doctors choose better treatments. Researchers compared genetic information with how patients responded to their first chemotherapy. This is …

This study looked at whether it is safe and possible to grow mini-tumors (organoids) from pancreatic cancer samples in the lab. 60 patients with pancreatic cancer provided tumor tissue during surgery or biopsy. The goal was to see if these organoids could be used to test differen…

This study looked at 200 patients with early-stage pancreatic cancer who had Whipple surgery. Researchers found that some patients developed fatty liver within six months after surgery, which may affect nutrition, blood sugar control, and long-term survival. The goal is to help d…